Avior Wealth Management LLC Increases Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Avior Wealth Management LLC increased its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 29.1% in the fourth quarter, Holdings Channel.com reports. The firm owned 1,190 shares of the biopharmaceutical company’s stock after acquiring an additional 268 shares during the period. Avior Wealth Management LLC’s holdings in Regeneron Pharmaceuticals were worth $848,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. Rakuten Securities Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 380.0% in the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 19 shares in the last quarter. FSA Wealth Management LLC purchased a new stake in Regeneron Pharmaceuticals during the 3rd quarter valued at $26,000. Fairfield Financial Advisors LTD purchased a new stake in Regeneron Pharmaceuticals during the 3rd quarter valued at $37,000. Truvestments Capital LLC purchased a new stake in Regeneron Pharmaceuticals during the 3rd quarter valued at $39,000. Finally, Valley Wealth Managers Inc. purchased a new stake in Regeneron Pharmaceuticals during the 3rd quarter valued at $49,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Analyst Upgrades and Downgrades

REGN has been the subject of several analyst reports. JPMorgan Chase & Co. dropped their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating for the company in a research report on Thursday, October 24th. Canaccord Genuity Group initiated coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target for the company. Oppenheimer dropped their price target on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a research report on Wednesday, November 6th. UBS Group cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price target for the company from $1,130.00 to $738.00 in a research report on Thursday, January 16th. Finally, Wells Fargo & Company decreased their price objective on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating for the company in a report on Friday, January 10th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $1,015.38.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $675.79 on Friday. Regeneron Pharmaceuticals, Inc. has a one year low of $666.25 and a one year high of $1,211.20. The company’s 50-day moving average is $728.81 and its 200 day moving average is $940.38. The company has a market capitalization of $74.26 billion, a price-to-earnings ratio of 16.72, a price-to-earnings-growth ratio of 1.59 and a beta of 0.10. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.